Výsledky vyhledávání

6.8 A 100Gb/s NRZ Transmitter with 8-Tap FFE Using a 7b DAC in 40nm CMOS

Autor: Sheng-Tsung Lai, Wei-Chien Huang, Chiang-Wei Lin, Pen-Jui Peng, Ted Shih, Wei-Hung Wang

Publikováno v: ISSCC

Recently, PAM-4 transmitters have been realized at 112Gb/s or even faster to satisfy the continuously growing demands for wireline communications [1]–[5]. Although PAM-4 signaling performs two-fold bandwidth efficiency compared with the NRZ counter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1739031dc4d9d659cb2d9943cc9395e
https://doi.org/10.1109/isscc19947.2020.9062934

Zobrazit plný text záznamu

6.7 A 112Gb/s PAM-4 Voltage-Mode Transmitter with 4-Tap Two-Step FFE and Automatic Phase Alignment Techniques in 40nm CMOS

Autor: Ted Shih, Chao-Hsuan Chen, Pen-Jui Peng, Hsiang-En Huang, Sheng-Tsung Lai, Yan-Ting Chen

Publikováno v: ISSCC

The continuous development of wireline communication encourages transmitters to operate at higher speeds. The applications of 400GbE also push the transmitter to be designed at 112Gb/s for a single lane [1–2]. However, the use of advanced processes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f130c2660ce5e454d1c2de7e3cb81a89
https://doi.org/10.1109/isscc.2019.8662361

Zobrazit plný text záznamu

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Autor: Murali Janakiram, Jeffrey S. Miller, Sara Weymer, Ted Shih, Yu-Waye Chu, Bahram Valamehr, David S. Siegel, Ravi Vij

Publikováno v: Blood. 136:3-3

Background: Allogeneic natural killer (NK) cell therapies have been well-tolerated with documented anti-tumor activity in patients with relapsed/refractory (r/r) hematologic malignancies including acute myelogenous leukemia (AML) and multiple myeloma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0701776c78640017549f93eaab5e52c
https://doi.org/10.1182/blood-2020-137715

Zobrazit plný text záznamu

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Autor: Anna M. Johnston, Wenyu Li, Gareth P. Gregory, Sasanka M. Handunnetti, Wei-Li Zhao, Yuan Liu, H. Miles Prince, Xiaoping Zhang, Judith Trotman, Stephen Opat, Aichun Liu, Ted Shih, Ken Wu, Jane Huang, Constantine S. Tam, Costas K. Yannakou, Gavin Cull, Fernando Roncolato

Publikováno v: Blood. 134:1594-1594

Background: Zanubrutinib is an investigational, next-generation BTK inhibitor, designed to maximize BTK occupancy and minimize off-target inhibition of TEC- and EGFR-family kinases. It has been shown to be highly potent, selective, bioavailable, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b19fd8af09b0a6b20ce4c82f0a0e51b
https://doi.org/10.1182/blood-2019-125485

Zobrazit plný text záznamu

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Autor: Amita Joshi, Yu-Waye Chu, Ola Saad, Sandhya Girish, David Loecke, Patricia LoRusso, Manish Gupta, Timothy J. Carrothers, Ted Shih, Joo-Hee Yi, Bei Wang

Publikováno v: Clinical Pharmacology in Drug Development. 2:11-24

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in development for human epidermal growth factor receptor 2 (HER2)-positive cancer. Drugs in development are generally tested for their effects on QT interval, prolongation of which is assoc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac360ac33ed44421b627db1626b97158
https://doi.org/10.1002/cpdd.9

Zobrazit plný text záznamu

Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer

Autor: E. Claire Dees, Bei Wang, Joo-Hee Yi, Javier Cortes, Sandhya Girish, Ted Shih, Yu-Waye Chu, Liang Fang, Howard A. Burris, Manish Gupta, Amita Joshi, Dan Lu

Publikováno v: Current Drug Metabolism. 13:911-922

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine) linked by a stable linker N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC). T-DM1 targets

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9a07579688e2964578d0312c114c0d1
https://doi.org/10.2174/138920012802138688

Zobrazit plný text záznamu

Pharmacogenetics: From Bench Science to the Bedside

Autor: Manoli Vourvahis, Julie I. Papay, Madhu Singh, Ted Shih

Publikováno v: Drug Information Journal. 42:503-513

Pharmacogenetics has received considerable attention in recent medical news. Extensive research has been conducted to better understand how an individual patient may respond to and benefit from a particular drug. The clinical application of pharmacog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::407756e7be338bc6b8da903a143c03a3
https://doi.org/10.1177/009286150804200511

Zobrazit plný text záznamu

Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies

Autor: Ted Shih, Celeste Lindley

Publikováno v: Clinical Therapeutics. 28:1779-1802

Bevacizumab is a recombinant humanized monoclonal antibody that was approved by the US Food and Drug Administration (FDA) in February 2004 for use as part of combination therapy with fluorouracil-based regimens for metastatic colorectal cancer (mCRC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe1896893a0952d04b7a24cd96f31c23
https://doi.org/10.1016/j.clinthera.2006.11.015

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání